TABLE 1.

Antitumor therapy together with ferroptosis inducers

Tumor type	Ferroptosis inducer	Combination	Target	Mechanism	Ref.
Acute myeloid leukemia	Erastin	Cytarabine and doxorubicin /adriamycin	GPX4	JNK and p38 synergistically promote erastin‐induced ferroptosis	[140]
Breast cancer	Albiziabioside A	Dichloroacetate	GPX4	AlbA‐DCA can inhibit GPX4 and eliminate M2 macrophages to promote antitumor immunity	[156]
Breast cancer	Ferroptosis inducers	Oxygen‐boosted PDT	–	PDT promotes the accumulation of lymphocytes at the tumor site and stimulates the secretion of IFN‐γ	[158]
Glioblastomas	Sulfasalazine	Gamma knife radiosurgery	System Xc‐	SSZ inhibits the uptake of cystine and therefore reduces the level of GSH, thus increasing the intracellular ROS	[149]
Head and neck cancer	Trigonelline	Artesunate	NRF2	NRF2 inhibitor trigonelline can induce lipid peroxide accumulation	[134]
Lung cancer	RSL3	Cisplatin	GPX4	RSL3 enhances the therapeutic effect of cisplatin	[123]
Melanoma	TGF‐β inhibitor	PD‐1 antibody	ROS	PD‐1 antibody and TGF‐β inhibitor cooperatively polarize M2‐TAMs into M1‐TAMs and promote the Fenton reaction with Fe ions discharged from magnetic nanoclusters	[155]
NSCLC	Erastin	Cisplatin	GSH‐GPX4	Cisplatin can deplete the GSH and inactivate the GPX4 together	[122]
NSCLC	Erastin	Cisplatin	ROS	SAHA and erastin, the inducers of ROS‐mediated cell death, strongly enhanced the effect of cisplatin in WT EGFR cells	[126]
Ovarian cancer	Erastin	Cisplatin	System Xc‐	Erastin can inhibit system Xc‐ and potentiate the cytotoxic effects of cisplatin to eradicate tumor cells	[125]
PDAC	Erastin	Gemcitabine	System Xc‐	Both SLC7A11‐KO cell lines exhibit amino acid stress with induction of ATF4 and cell death	[124]
PDAC	Erastin	Cisplatin	System Xc‐	Both SLC7A11‐KO cell lines exhibit amino acid stress with induction of ATF4 and cell death	[124]
Sarcoma	Anti–PD‐L1/Anti‐ CTLA‐4 mAb	Ionizing radiation	System Xc‐	Radiation therapy and interferon synergistically reduce the expression level of SLC7A11	[151]